TITLE

Biogen Stock Hits New High After MS OK

AUTHOR(S)
AMY REEVES
PUB. DATE
March 2013
SOURCE
Investors Business Daily;3/28/2013, pA04
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
Shares of
ACCESSION #
86416084

 

Related Articles

  • Biogen Idec/Elan: Antegren could shake up MS treatment market.  // PharmaWatch: CNS;August 2004, Vol. 3 Issue 8, p4 

    Antegren, a humanized monoclonal antibody, potentially offers superior efficacy, combined with a more convenient once-monthly dosage regime. In addition to use as a monotherapy, Antegren is being investigated in combination with Avonex - a potentially highly lucrative opportunity for Biogen...

  • Oil, Gas Stocks Dominate New-Highs List; GasLog Leads. SCOTT STODDARD // Investors Business Daily;4/15/2014, pB05 

    Oil and gas stocks dominated a short new-highs list on Monday, but many reversed lower after hitting fresh peaks.

  • A Sharp Negative Reversal Often Flags A Good Stock's Top. DAVID SAITO-CHUNG // Investors Business Daily;10/1/2014, pB06 

    When a stock hits a new high, it's human to respond to such news with joy.

  • New Highs. ELLIOTT, ALAN R. // Investors Business Daily;12/20/2016, p1 

    The article offers information on three growth stocks which hit new highs.

  • Biogen up on Tecfidera growth. Investor's Business Daily // Investors Business Daily;4/30/2013, pA02 

    The biotech's shares hit a new high of 225 before closing at 223.61 after drug tracker IMS Health reported 730 total prescriptions of the multiple-sclerosis drug in the 3rd week of its launch, up 120% from the previous week. An analyst at RBC Capital Markets noted Tecfidera is stomping the...

  • Actavis Soars, Questcor Falls. Investor's Business Daily // Investors Business Daily;10/30/2013, pA01 

    7 Actavis' ([STOCK[ACT]]) Q3 profit hiked 55% and sales rose 57% to $2.01 bil, meeting expectations. The drugmaker's stock hit a new high after guidance topped views.

  • Biogen Idec case study.  // Biogen Idec Case Study: Securing Long-Term Growth in the MS Mark;Aug2007, p1 

    • Since the initial launch in 1997, Biogen Idec has focused extensive efforts on growing the sales of its MS drug Avonex and has invested considerably in the development of its future MS franchise. This includes gaining marketing approval for Avonex for patients at high risk of developing...

  • Pent-up demand should drive Tecfidera, docs say. McCaffrey, Kevin // Medical Marketing & Media;May2013, Vol. 48 Issue 5, p10 

    The article reports on high demands towards multiple sclerosis (MS) drug, Tecfidera, from Biogen Idec Inc.

  • Spain Yields Hit Record High. Investor's Business Daily // Investors Business Daily;7/23/2012, pA01 

    2.� �The 10-year yield, after a quiet return above 7% Thu., leapt 26 basis points to 7.28%, a euro-era high after Valencia said it'll seek central gov't aid, raising fears that recession-hit Spain will need a full sovereign bailout. Big anti-austerity protests ended in Madrid early...

  • Biogen Idec's Daclizumab Looking Good in Phase IIb. Shaffer, Catherine // BioWorld Today;8/10/2011, Vol. 22 Issue 154, p1 

    The article reports on the positive results obtained by Biogen Idec Inc. from the Phase IIb trial of daclizumab high-yield process (DAC HYP), its multiple sclerosis (MS) candidate. Results of the trial showed that DAC HYP led to a significant reduction in annualised relapse rate. It notes that...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics